Blog 28: Silly Patent: Allergan Suing Sandoz for Patent Infringement

Allergan is suing Sandoz for marketing a generic version of their patented drug COMBIGAN, which is a combination ophthalmic drug treatment. Sandoz went to the FTC trying and their major claim is 463, which is proving Alergan’s patent of COMBIGAN is not obvious. However this is silly, because it has the same chemicals and functions. The only significance part was the 4^th

part of claim 463 which shows that Sandoz  is a different drug because it changes the amount of time for the drug to kick in. For a drug this is not enough to make it different, because all a manufacture needs to do is make one more or less dissoluble for the body. Sandoz still lost this claim and is not allowed to patent or market this new drug until 2022, when Allergan’s patent expires.

http://www.patentlyo.com/patent/2013/05/allergan-v-sandoz-the-thin-line-of-nonobviousness.html

Blog 27: Silly Google Losing Injunction Battle Vs. Apple

Google is in the news yet again for another court failure. In Wisoconsin the Federal circuit court of appeal denied Google’s attempts to get an injunction ruling brought by Apple to be lifted or moved to another court. The injunction was brought on many Samsung products and with the use of a FRAND patent.

Some lower courts are trying to force Google to pay Apple’s FRAND licensing fee. However, Apple is trying to stray away from that court and focus on the injunctions. The author thinks that this case is one of the most significant cases for Google. These past few months have proven that Motorola’s patents have proven to be mostly a silly investment. Android will have to be more strategic in buying and licensing patents.        

http://www.fosspatents.com/2013/05/federal-circuit-denies-google-motion-to.html